Randomized Trialhigh evidence
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
The lancet. Diabetes & endocrinology·August 21, 2026·PMID 42628555
Why it mattersObesity management increasingly relies on incretin-based therapies, but dual glucagon/GLP-1 agonism may offer greater weight loss than GLP-1 alone. Mazdutide's efficacy at 10 mg and 16 mg approaches that of bariatric surgery, potentially expanding options for patients needing substantial weight reduction.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled